Sun Pharma the latest to recall metformin after carcinogen tests come up positive

Sun Pharma
Sun is now the eighth drugmaker to launch a voluntary recall of their version of metformin. (Sun)

Once cleared by the FDA of a probable carcinogen, generic diabetes med metformin has now been the target of a growing number of recalls. This week, a seventh drugmaker has joined the metformin recall parade after finding high levels of a potential cancer-causing contaminant.

Sun Pharma recalled one lot of its Riomet ER, an extended-release version of the common diabetes med, after testing showed high levels of N-nitrosodimethylamine (NDMA), the drugmaker said Wednesday.

The recalled lot contains 747 bottles of the drug with an expiration date of October 2021, Sun said in a release. 

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

Sun is now the eighth drugmaker to launch voluntary recalls of their versions of metformin after the FDA earlier this year found high levels of NDMA, a contaminant connected to global recalls of "sartan"-based heart pressure drugs and heartburn med Zantac, in tested lots. 

RELATED: Metformin recalls continue as Bayshore pulls diabetes drug on carcinogen scare

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.